Table 3 PCSM in general, comparison by race.

From: The impact of race on survival in metastatic prostate cancer: a systematic literature review

Study

Populationa

Type of analysis/results

Whiteb

Blackc

Asiand

Hispanice

AI/ANf

HR (95% CI), p-value

Bernard (2017) [22]

mCSPC

Multivariable

Reference

1.00 (0.94–1.06), p = 0.982

0.81 (0.74–0.89), p < 0.001

0.94 (0.87–1.01), p = 0.094

1.23 (0.95–1.59), p = 0.119

Zhang (2021) [38]

mCSPC

Multivariable

Reference

1.04 (0.99–1.09), p = 0.10

0.77 (0.71–0.84), p < 0.0001

0.95 (0.89–1.00), p = 0.06

1.04 (0.84–1.28), p = 0.7

Deuker (2020)g[50]

mCSPC

Multivariable

Reference

NR

NR

NR

1.04 (0.80–1.36), p = 0.7

Bernard (2020)h[21]

mCSPC

Multivariable

Reference

1.12 (1.02–1.23), p = NR

0.70 (0.59–0.83), p = NR

1.00 (0.89–1.13), p = NR

1.27 (0.81–2.00), p = NR

Borno (2020) [23]

Mixed

Multivariable

Reference

1.20 (0.92–1.57), p = 0.1754

NR

1.20 (0.67–2.17), p = 0.5363

NR

Würnschimmel (2021)g[37]

mCSPC

Multivariable

Reference

0.93 (0.77–1.12)i, p = 0.4

0.59 (0.4–0.80)i, p < 0.0001

0.69 (0.56–0.87)i, p = 0.001

NR

Würnschimmel (2021)g[44]

mCSPC

Multivariable

Reference

1.01 (0.90–1.13), p = 0.8

0.63 (0.51–0.77), p < 0.001

0.97 (0.85–1.12), p = 0.75

NR

Deuker (2021)g[24]

mCSPC

Multivariable

Reference

NR

0.62 (0.57–0.69), p < 0.01

NR

0.86 (0.67–1.11), p = 0.2

Taksler (2012) [61]

mCSPC

Unclear

Reference

j

NR

NR

NR

Patel (2018) [31]

mCRPC

Multivariable

Referencek

0.94 (0.75–1.17), p = NR

NR

NR

NR

He (2021) [26]

Regional mCSPC

Multivariable

1.13 (0.93-1.38), p = 0.2089

Reference

0.74 (0.51–1.06), p = 0.1024

NR

1.97 (1.08–3.58), p = 0.0276

Distant mCSPC

Multivariable

0.99 (0.91-1.08), p = 0.8534

Reference

0.66 (0.56–0.78), p < 0.0001

NR

0.93 (0.61–1.42), p = 0.7342

  1. AI/AN American Indian and Alaska Native, CI confidence interval, HR hazard ratio, mPC metastatic prostate cancer, mCRPC metastatic castration resistant prostate cancer, mCSPC metastatic castration sensitive prostate cancer, NR not reported, PCSM prostate cancer-specific mortality.
  2. amCSPC and mCRPC population was assessed based on clinical judgement in instances that population was not explicitly stated in the text.
  3. bColumn includes results for populations such as White, Non-Hispanic White, etc.
  4. cColumn includes results for populations such as Black, Non-Hispanic Black, etc.
  5. dColumn includes results for population such as Asian, Non-Hispanic Asian, Asian/Pacific Islander, etc.
  6. eColumn includes results for populations such as Hispanic, Hispanic (all races), Hispanic (White), etc.
  7. fColumn includes results for population such as AI/AN, Native American, etc.
  8. gResults shown for cancer-specific mortality (rather than PCSM).
  9. hResults shown correspond to multivariable model that adjusted for the most complete set of covariates.
  10. i97.5% CI.
  11. jStudy reported that “mortality did not differ significantly by [Black versus White] race for metastatic [prostate] cancers”
  12. kNon-Black.
Back to article page